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Abstract. Epidemiological and in vitro data have not provided 
conclusive evidence concerning the involvement of thyroid 
hormones (THs) on mammary carcinogenesis. We used an 
in vivo model to assess the relationship between THs, adipose 
tissue and breast cancer development. Female Sprague-Dawley 
rats were treated with a dose of 7,12-dimethylbenz(a)anthra-
cene (15 mg/rat) at 55 days of age and were then divided into 
four experimental groups: hypothyroid rats (HypoT, 0.01% 
6-N-propyl-2-thiouracil in drinking water), untreated control 
(EUT); hyperthyroid rats (HyperT, 0.25 mg/kg/day T4 s.c.) and 
vehicle-treated control rats. The latency of tumor appearance 
and the incidence and progression of tumors were determined. 
At sacrifice, blood samples were collected for hormone deter-
minations and samples of tumor and mammary glands were 
obtained for immunohistological studies. HypoT rats had 
retarded growth and an increase in mammary fat. The latency 
was longer (p<0.0001), the incidence rate was lower (p<0.05) 
and tumor growth was slower in HypoT rats compared to EUT 
and HyperT rats. Mitotic index and PCNA immunostaining 
were similar in all groups. HypoT rats showed increased apop-
tosis (p<0.05) as evaluated by the apoptotic index and TUNEL 
staining. No differences in serum prolactin and progesterone 
were observed. However, circulating estradiol (E2) was signifi-
cantly lower in HypoT and HyperT rats. Serum leptin levels 
were reduced in HypoT rats even though the abdominal fat 
mass was similar in all groups. To note, the leptin level was 
higher in HypoT rats that developed mammary tumors than 
the level in non-tumoral HypoT rats. In conclusion, hypo-
thyroidism altered animal growth, breast morphology, body 
composition, leptin secretion and serum E2 enhancing apop-
tosis and, consequently, retarding mammary carcinogenesis 
in rats.
Introduction
Mammary development and breast carcinogenesis are 
usually characterized by their hormonal control (1). Among 
the hormones more frequently studied, estrogens (E) and 
progesterone (Pg) regulate several functions of the normal or 
tumoral mammary epithelium, such as cell proliferation and 
apoptosis. Approximately one-third of breast cancers maintain 
E-dependence for growth and the concentration of estrogen 
receptors (ERs) in malignant breast tissues is an indicator of 
this hormonal dependence (2). E are the main steroid hormones 
implicated in the induction of breast cancer, but experimental 
evidence in rodents suggests that Pg is also important in its 
induction and progression (3).
Prolactin (PRL) has been associated with breast cancer 
pathogenesis and progression. Acting at the endocrine and 
autocrine/paracrine levels, PRL functions to stimulate 
the growth and motility of human breast cancer cells (4). 
Epidemiologic studies have demonstrated that hyperprolac-
tinemia is frequently associated with growth, development 
and a poor prognosis in mammary cancer (5). Related to PRL 
actions on mammary gland, the growth hormone (GH) has 
also been shown to affect mammary development and carci-
nogenesis. In rodents, GH may potentiate breast cancer since 
GH- or GH receptor-deficiency is associated with reduced 
incidence and aggressiveness of experimentally induced breast 
cancer (6).
Other hormonal influences on the mammary gland involves 
triiodothyronine (T3) and activation of mammary thyroid 
hormone receptors (TRs) inducing differentiation and lobular 
growth in an E-like manner. However, there is controversy 
concerning the relationship between thyroid disorders and 
breast cancer incidence (7). Thyroid hormones (THs) could 
participate directly on mammary carcinogenesis, or indirectly 
through their action in changes in the patterns of secretion of 
other hormones such as E, Pg, PRL and/or GH, among others. 
It has been shown that hypothyroidism may result in reduced 
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incidence of primary breast carcinoma (8), and in vitro studies 
also suggest that THs affect cell proliferation and gene expres-
sion (9).
Moreover, THs have important effects on energy balance, 
since they influence both energy intake and expenditure. 
Abnormal TH levels are frequently associated with changes 
in body weight and modifications in the function of adipose 
tissue. The adipocyte is a functionally active cell and produces 
several biologically active adipokines such as leptin, which 
could contribute to an increased breast cancer risk for obese 
women (10). Furthermore, estradiol (E2) is also produced by 
adipose tissue and it has been suggested as being responsible 
for the elevated risk of breast cancer in these women (10).
Since the epidemiologic and in vitro data have not 
provided conclusive evidence of the involvement of THs in 
mammary carcinogenesis, we used an in vivo model to assess 
the relationship between THs, adipose tissue and breast 
cancer development. In the present study, we investigated the 
effect of the hormonal milieu induced by hypothyroidism or 
hyperthyroidism on mammary carcinogenesis induced by 
7,12-dimethylbenz(a)anthracene (DMBA) in rats.
Materials and methods
Animals. Virgin Sprague-Dawley female rats (180-200 g) bred 
in our laboratory were used. The animals were maintained in 
a light- (lights on from 06.00 to 20.00 h) and temperature-
controlled room (22-24˚C); rat chow (Cargill, Córdoba, 
Argentina) and tap water or 6-N-propyl-2-thiouracil (PTU) 
solution were available ad libitum.
Animal maintenance and handling were performed 
according to the NIH guide for the Care and Use of Laboratory 
Animals (NIH publication no. 86-23, revised 1985 and 1991) 
and the UK requirements for ethics of animal experimenta-
tion (Animal Scientific Procedures, Act 1986). All the 
experimental procedures were approved by the Animal and 
Ethics Committee of the School of Medicine of the National 
University of Cuyo, Mendoza, Argentina.
Experimental protocols. In order to study the effect of hypo-
thyroidism or hyperthyroidism on mammary carcinogenesis, the 
rats were treated per os with a single dose of DMBA (15 mg/rat) 
at 55 days of age and were then divided into two experimental 
groups and their respective controls: hypothyroid rats (HypoT, 
n=26) and untreated rats (EUT, n=12); hyperthyroid rats (HyperT, 
n=23) and vehicle-treated rats (VEH, n=5). The day of DMBA 
administration was considered as day 0 of the experiment.
Hypothyroidism was induced by the administration of 
PTU (Sigma-Aldrich, Buenos Aires, Argentina) at a concen-
tration of 0.1 g/l in the drinking water, starting on day 3. The 
respective control group (EUT) was maintained under stan-
dard conditions during the study period.
Hyperthyroidism was induced by daily subcutaneous 
administration of L-thyroxine (T4; Sigma-Aldrich). T4 was 
dissolved in saline solution (0.42 N of NaOH) and injected s.c. 
daily at a dose of 0.25 mg/ml/kg starting on day 3. Control 
age- and weight-matched female rats received VEH s.c.
Since no statistical differences were observed between 
the EUT and VEH groups in any of the studied variables, we 
grouped and analyzed them as a single control group.
Body weight was monitored weekly. Food intake was 
assessed on week 10 of the experiment and expressed as the 
weight of rat chow consumed per rat and per day. The animals 
were assessed every 72 h for the appearance of the first palpable 
tumor. The latency, incidence and progression of tumors were 
determined in all groups. The rats were sacrificed by decapita-
tion at 10:00 h on the day of diestrus when the tumors reached a 
volume >1,000 mm3 or at the end of the experiment on day 200 
when they did not develop mammary tumors. All the animals 
were weighed and their vaginal smears observed before 
sacrifice. Trunk blood samples were collected and allowed to 
clot at room temperature. Serum was separated and stored at 
-20˚C until assayed for hormone determinations. Immediately 
after decapitation, intra-abdominal fat was removed, weighed 
and expressed as a percentage of total body weight. A piece 
of normal mammary gland and the tumors were removed for 
histopathological and immunohistochemical analysis.
Induction of mammary tumors. DMBA (Sigma-Aldrich) was 
dissolved in sunflower oil at a concentration of 5 mg/ml and 
administered at a dose of 15 mg/rat on day 0 by an intragastric 
probe, 3 h after food and water deprivation to ensure a complete 
absorption of the drug. Food and water were replaced 2 h after 
DMBA administration. DMBA has been extensively used at 
that dose to study the possible mechanisms responsible for the 
beginning of the transformation of normal breast tissue into a 
tumor (11).
Hormone determinations. Thyroid stimulating hormone 
(TSH), PRL and GH concentrations were measured by double 
antibody radioimmunoassay using materials generously 
provided by A.F. Parlow and the National Hormone and 
Pituitary Program (NHPP, Harbor-UCLA Medical Center, 
Torrance, CA, USA). The hormones were radio-iodinated 
using the chloramine T method and purified by passage 
through Sephadex G75. The results were expressed in terms 
of the rat TSH RP-3, rat PRL RP-3 or rat GH RP-2 standard 
preparations. Assay sensitivity was 0.5 µg/l serum and the 
inter- and intra-assay coefficients of variation were <10% for 
all hormones.
E2, Pg, T3 and tetraiodothyronine (T4) concentrations in 
sera were measured by radioimmunoassay using commercial 
kits for total hormones (TKE 21 and TKPG1 double antibody 
radioimmunoassay; Siemens Healthcare Diagnostics, Inc., Los 
Angeles, CA, USA and RK-6CT1 and RK-1CT1 double anti-
body radioimmunoassay; Institute of Isotopes Ltd., Budapest, 
Hungary; respectively). Inter- and intra-assay coefficients of 
variation were <10%.
Serum leptin concentrations were determined by a specific 
radioimmunoassay developed in the Instituto Multidisciplinario 
de Biología Celular (IMBICE) and validated for rat and 
mouse leptin against a commercial kit (catalog no. RL-83K; 
Linco Research, Inc., St. Charles, MO, USA) as previously 
published (12). Briefly, synthetic murine leptin (PrePro Tech, 
Inc., Rocky Hill, NJ, USA) was used for both labeled peptide 
and standard and for the development of anti-leptin serum. 
Leptin was radio-iodinated by the chloramine T method and 
purified by elution using a Sephacryl S-300 (Sigma-Aldrich) 
column. The anti-leptin serum was developed by rabbit immu-
nization with murine leptin coupled to BSA. The intra- and 
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inter-assay coefficients of variation were 5-8 and 10-13%, 
respectively.
Latency, incidence and progression of tumors. The latency of 
mammary tumors was considered as the time between DMBA 
administration and the appearance of the first palpable tumor. 
Incidence was calculated as the percentage of rats that had 
tumors within the study period in respect to the total number 
of rats per group. We used a caliper to measure the major (DM) 
and minor (dm) diameters every 72 h and calculated the tumor 
volume (TV = dm2 x DM/2). Tumor progression was assessed 
estimating tumor growth rate [GR = TV/(day of sacrifice - day 
of appearance of first tumor)].
Tumors and mammary gland histology. Small pieces of the 
tumor and inguinal mammary gland (contralateral to the 
tumor) from each rat were processed for histopathologic studies 
by fixing in buffered formalin, dehydrating in ethanol and 
embedding in paraffin wax. Sections (3-5 µm) were cut with a 
microtome and stained with hematoxylin and eosin (H&E) to 
define the histopathological changes in the mammary glands 
and to classify tumors according to published criteria (13). 
Images were captured with an Eclipse E200 microscope fitted 
with a digital still camera Micrometrics SE Premium (both 
from Nikon Corp., Japan) under magnification of x100, x400 
and x600.
The quantification of the percentages of stroma, mostly 
composed by adipocytes, and epithelial tissue in the mammary 
gland was performed by measuring the area occupied by the 
adipose tissue or epithelium in 8-10 fields of each preparation 
from all rats using the ImageJ 1.42q software available at the 
NIH site (http://rsb.info.nih.gov/ij). Each area was expressed 
as a percentage of the whole field as previously published (14).
Apoptotic and mitotic indices. The microscopic analysis was 
carried out by two independent observers. The apoptotic and 
mitotic indices were calculated by counting the total number 
of apoptotic bodies and mitotic figures, respectively, in the 
histological sections stained with H&E in 10 x400 magnifi-
cation-fields from each animal. The mitotic/apoptotic ratio 
(M/A ratio) was calculated by dividing the mitotic index by 
the apoptotic index.
Immunohistochemistry (IHC). Serial sections (3-5 µm) were 
mounted onto 3-aminopropyltriethoxysilane (Sigma-Aldrich)-
coated slides for subsequent IHC analysis. The primary 
antibody used in this study was a monoclonal mouse anti-
proliferating cell nuclear antigen (PCNA; Dako Cytomation, 
Glostrup, Denmark) at 1:500. An antigen retrieval protocol 
using heat was used to unmask the antigens (30 min in citrate 
buffer, 0.01 M, pH 6.0). Tissue sections were incubated with 
the primary antibody overnight at 4˚C in humidity chambers. 
A commercial kit to detect mouse and rabbit antibodies 
was used (Dako EnVision system, horseradish peroxidase, 
diaminobenzidine; Dako, Carpinteria, CA, USA). Slides were 
lightly counterstained with hematoxylin to reveal the nuclei, 
examined and photographed. The percentage of positive nuclei 
was obtained based on an average of 700 cells counted per 
sample, at a x400 magnification. The immunostaining of the 
tumor cells was semi-quantitatively scored as: 0, no staining; 
1, nuclear staining of <10% of tumor cells; 2, staining between 
11 and 33% of tumor cells; 3, staining between 34 and 65% 
of tumor cells; 4, staining of >66% of tumor cells. These 
scores were obtained by two independent observers blinded 
regarding the clinical evaluation, and a few conflicting scores 
were resolved by consensus.
TUNEL. Apoptosis was measured by a modification of the 
TUNEL assay using the ApopTag Plus Apoptosis In Situ 
Detection kit (Oncor, Gaitherburg, MD, USA), as reported 
previously (15). The TUNEL apoptotic index was calculated 
as the percentage of positive nuclei, based on an average of 
700 cells counted per case, at x400 magnification.
Statistical analysis. Values are expressed as means ± SEM 
of 17-26 animals/group. All statistical analyses were 
performed using GraphPad Prism 5.01 software (GraphPad 
Software, Inc., San Diego, CA, USA). Differences in the 
distribution of variables between the three studied groups 
(HypoT, HyperT and controls) were assessed using one-way 
analysis of variance (ANOVA I) or the Kruskal Wallis test 
depending on the normality of the variables as evaluated by 
the Kolmogorov-Smirnov test. Two-way analysis of variance 
(ANOVA II) was used for analysis of the effects of the PTU or 
T4 treatments on body weight over time. Post hoc comparisons 
between means were conducted by Bonferroni's test or Dunn's 
multiple comparison test. Student's t-test was used when only 
two groups were compared. When variances were not homo-
geneous, logarithmic transformation of data was applied. 
Incidence and percentages of mammary adipose area were 
analyzed by Chi-square. Survival curves were compared using 
the log-rank Mantel-Cox test. The relation between selected 
variables was performed by Pearson's correlation coefficient. 
Differences were considered significant when the probability 
was 5% or less.
Results
Induction of hypothyroidism and hyperthyroidism. The chronic 
thyroid condition of the animals was evaluated by measuring 
serum T4, T3 and TSH concentrations. The rats treated with 
PTU had low circulating T4 (20.96±1.10 ng/ml, p<0.001) and T3 
(0.42±0.06 ng/ml, p<0.05) concentrations and also markedly 
increased levels of TSH (4.98±0.43 ng/ml, p<0.01) compared 
to the EUT rats (33.29±2.62, 0.61±0.06 and 0.84±0.06, 
respectively); all of them sensitive indicators for hypothy-
roidism. In contrast, L-thyroxine administration increased T4 
(55.88±6.93 ng/ml, p<0.05) and T3 (0.91±0.10 ng/ml, p<0.05) 
and decreased circulating TSH (0.52±0.02 ng/ml, p<0.01) 
confirming the state of hyperthyroidism.
Hypothyroidism affects food intake, body weight and growth 
of the animals. Chronic treatment with PTU significantly 
retarded the growth of the HypoT animals as reflected in 
the decreased weight and reduced levels of circulating GH 
(Table II) in comparison with the HyperT rats and the untreated 
controls. HypoT rats had an increase in body weight similar to 
HyperT and EUT rats during the first 4 weeks of treatment 
with PTU. Afterwards, they stopped gaining weight until 
the end of the study showing a significant difference in body 
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weight when compared with the other two groups (p<0.0001, 
data not shown). HyperT rats gained weight steadily similar 
to the EUT rats. Daily food intake was significantly lower in 
HypoT rats compared to HyperT and EUT rats (12.6±0.2 vs. 
23.2±1.2 and 19.1±0.7 g/rat, respectively; p<0.0001).
The mass of abdominal fat expressed as a percentage of the 
body weight has been previously used as a measure of body 
composition in rats (16). No statistically significant change 
was observed in this percentage due to PTU (11.3±1%) or T4 
(9.1±0.6%) treatments compared with controls (11.5±0.7%), 
although the HyperT rats had a tendency to show lower 
values.
Effects of hypothyroidism and hyperthyroidism on mammary 
gland histology. The effect of THs on the development of 
the mammary gland was evaluated by histological observa-
tion and measurement of the areas occupied by parenchyma 
or stroma. Table I shows that the mammary glands of EUT 
rats had a normal appearance with few ducts surrounded by 
a small amount of fibrous connective tissue and abundant 
adipose tissue. The mammary glands of HyperT and HypoT 
rats were also normal but in a few cases were associated with 
mammary benign pathologies such as ductal stasis. Moreover, 
hyperplasia, intraductal papilloma and adenosis were observed 
in the HyperT rats (Table I).
Fig. 1A-C show representative microphotographs of 
H&E-stained mammary tissue from HypoT, EUT and HyperT 
rats, respectively. Fig. 1D shows the relative percentages of the 
adipose area. In EUT and HyperT rats, ~80% of the mammary 
gland was composed of stroma, which consisted of fat and 
connective tissue. The rest of the gland was represented by 
the parenchyma including lobules type 1, lobules type 2 and 
ductal structures (Fig. 1B and C). In HypoT rats, a scarce 
lobe-alveolar development of the mammary gland (~10%) and 
an increased percentage of fat in the stroma (~90%, p<0.001 
compared to HyperT and EUT rats) were observed (Fig. 1D), 
suggesting that hypothyroidism, but not hyperthyroidism, 
induced changes in the parenchyma-stroma ratio.
Effects of hypothyroidism and hyperthyroidism on mammary 
gland carcinogenesis. Table I shows the histopathological 
characteristics of the tumors in the three groups. On one hand, 
tumors of EUT and HyperT rats were all of low grade consid-
ering the characteristics of the nuclei, the presence of ducts 
and the number of mitotic figures. They had a predominant 
in situ component with a small invasive component. Necrosis 
was scarce and they had moderate inflammatory infiltration. 
Thirty-three percent of EUT and 47% of HyperT rats devel-
oped secondary tumors. On the other hand, malignant tumors 
from HypoT rats were histologically more aggressive with a 
predominant invasive component and a small in situ compo-
nent. Necrosis was moderate and the host response was lower 
than in the tumors from HyperT and EUT rats.
The latency of onset of tumors was longer (p<0.05) 
(Fig. 2A) and the incidence was lower (p<0.0001) (Fig. 2B) in 
the HypoT rats when compared to the EUT and HyperT rats. 
Hypothyroidism retarded tumor growth (p<0.05) (Fig. 2C) 
and increased tumor-free survival (p<0.001) (Fig. 2D). No 
relationship between tumor growth rate and the histological 
type of the neoplasia was apparent in any of the groups.
Hypothyroidism increases apoptosis without promoting cell 
proliferation. To assess the effect of THs on tumor progres-
sion, we performed a microscopic analysis of mitosis and 
apoptosis. The mitotic index was similar in the three groups 
(Fig. 3A) while the apoptotic index tended to increase in 
Figure 1. Hypothyroidism modifies the ratio of parenchyma/stroma in the mammary gland. Representative microphotographs (x100) of H&E-stained mam-
mary tissues from (A) HypoT, (B) EUT and (C) HyperT rats. Arrows show lobules type 1 and arrowheads indicate lobules type 2. (D) Quantification of the 
relative percentages of adipose area. Values represent mean ± SEM of 8-10 fields of each preparation from 17-26 animals/group. **p<0.001 compared to HyperT 
and EUT rats. Comparisons were performed by Chi-square.
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tumors of the HypoT rats (p=0.07) (Fig. 3B). In order to inves-
tigate if the balance between mitosis and apoptosis influences 
tumor development we calculated the mitotic/apoptotic ratio. 
This parameter was significantly lower in HypoT rats when 
compared to EUT and HyperT animals (p<0.05) (Fig. 3C), and 
was positively correlated with the tumor growth rate (r=0.715; 
p=0.002) (Fig. 3D) suggesting that the difference in the M/A 
ratio had biological significance.
We further studied apoptosis by TUNEL assay, a more 
sensitive technique, and we found an increased number of 
TUNEL-positive cells in tumors of the HypoT rats compared 
to the numbers in the HyperT and EUT animals (p<0.05) 
(Fig. 4A-D). In order to validate the results obtained by 
counting mitotic figures, we additionally evaluated mitosis 
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Table I. Summary of mammary gland characteristics and 
tumors developed in the DMBA-treated rats.
 HypoT EUT HyperT
 rats rats rats
No. of rats 26 17 23
Mammary glands
  Normal 23 16 18
  Benign lesions 
    Hyperplasia   0   1   1
    Intraductal papilloma   0   0   1
    Adenosis   0   0   2
    Ductal ectasis   3   0   1
Tumors
  Rats with tumors   3 12 17
  Tumor weight (g)a 1.26±0.57 1.22±0.17 1.32±0.18
  Type of tumor 
    Ductal carcinoma   3 10 15
    Infiltrating lobular   0   2   0
    carcinoma
    Tubular carcinoma   0   0   2
  Ductal tumor grade
    I   1 10 13
    II   2   0   2
    III   0   0   0
  Other characteristics
    Predominant component Invasive In situ In situ
    Inflammatory response Low Moderate Moderate
    Necrosis Moderate Scarce Low
  Rats with secondary
  tumors
    Low-grade ductal   1   4   8
    carcinoma
aValues correspond to the mean ± SEM. The weight of tumors was not 
statistically different between the groups. DMBA, 7,12-dimethylbenz(a)
anthracene.
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by IHC of PCNA in the tumors. No statistically significant 
differences between the treatments were observed (Fig. 4E-H).
Hypothyroidism and hyperthyroidism alter hormone patterns. 
The influence of PTU and T4 treatments on circulating hormone 
concentrations is shown in Table II. Both treatments decreased 
circulating levels of E2 compared to EUT rats (p<0.0001).
Serum PRL and Pg concentrations were similar between 
the three studied groups. No significant differences were 
observed in circulating values of GH, PRL, E2 and Pg between 
Figure 3. Mitotic/apoptotic (M/A) ratio correlates with the tumor growth rate. (A) Mitosis and (B) apoptosis were evaluated by counting the total number of 
mitotic figures and apoptotic bodies, respectively, in histological sections stained with H&E of 10 microscopic fields (x400) from each animal. (C) The M/A 
ratio was calculated by dividing the mitotic index by the apoptotic index. Values represent the mean ± SEM of each group. Comparisons were performed 
by ANOVA I and Bonferroni's test as post hoc. *p<0.05, HypoT compared to HyperT and/or EUT rats. (D) Correlation between M/A ratio and tumor growth 
including all three treatment groups as evaluated by the Pearson's correlation coefficient. 
Figure 2. Hypothyroidism affects mammary carcinogenesis. (A) Latency of onset of mammary tumors, (B) percentage of rats developing primary and secondary 
tumors, (C) tumor growth rate and (D) the percentage of rats surviving without breast tumors. Values represent mean ± SEM of each group. Comparisons in 
latency and tumor growth were performed by ANOVA I and Bonferroni's test as post hoc. Incidence was expressed as percentages and compared by Chi-square 
test. Survival curves were compared using the log-rank Mantel-Cox test. *p<0.05; **p<0.001; ***p<0.0001, HypoT compared to HyperT and/or EUT rats.
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tumor-bearing and tumor-free rats in the HypoT, HyperT and 
EUT groups.
Effect of adipose tissue and leptin on mammary gland carci-
nogenesis. Leptin concentrations were significantly decreased 
in HypoT rats whether they were calculated per milliliter of 
serum or per gram of abdominal fat mass (p<0.05, Table II). 
This suggested that adipocyte secretion activity was altered in 
HypoT rats since the body fat mass was similar in all groups. 
Interestingly, serum leptin levels were higher in HypoT rats with 
Figure 4. Hypothyroidism increases apoptosis. Representative microphotographs (x600) of tumors immunostained to reveal TUNEL-positive cells from 
(A) HypoT, (B) EUT and (C) HyperT rats. Arrows show apoptotic cells revealed by TUNEL assay. (D) Number of TUNEL-positive cells/field. Values represent 
mean ± SEM of 8-10 fields of each preparation from 17-26 animals/group. *p<0.05 compared to HyperT and EUT. Comparisons were performed by ANOVA 
I and Bonferroni's test as post hoc. Hypothyroidism did not affect cell proliferation. Representative microphotographs (x400) of tumors immunostained to 
reveal PCNA from (E) HypoT, (F) EUT and (G) HyperT rats. Arrows show mitotic cells. (H) PCNA-inmunostaining score. Values represent mean ± SEM of 
8-10 fields of each preparation from 17-26 animals/group. Comparisons were performed by Kruskal-Wallis' test and Dunn's test.
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tumors than in those without tumors (1.3±0.4 vs. 0.6±0.1 ng/ml, 
respectively; p<0.05). No significant differences were observed 
in EUT or HyperT rats, regarding tumor presence.
Discussion
The possible association between thyroid diseases and breast 
carcinoma has been debated for decades and remains contro-
versial (8,13,17,18). Epidemiological and prospective studies 
have not been able to demonstrate a correlation between benign 
thyroid conditions and the risk of mammary cancer (13,18,19). 
However, other studies have supported a significant association 
between primary hypothyroidism and breast cancer (8,20). 
In the present study, hypothyroidism prolonged the latency 
of tumor appearance, reduced tumor incidence and retarded 
tumor growth in rats.
Martinez-Iglesias et al (21) injected MDA-MB-468 cells 
in hypothyroid mice and evaluated the growth of the tumors, 
thus avoiding the effect of THs on cancer initiation. They 
found that hypothyroidism had a dual effect on mammary 
tumorigenesis, since tumor growth was slower in hypothyroid 
mice, but the tumors were more aggressive and invasive, and 
the formation of metastasis was strongly enhanced. Contrarily, 
in humans, Cristofanilli et al (8) showed that spontaneous 
clinical hypothyroidism was a strong protective factor against 
mammary cancer and decreased tumor incidence and aggres-
siveness. These authors also found that women with primary 
hypothyroidism had a 61% reduction in the risk of invasive 
breast cancer and they were more likely to have localized 
disease and no lymph node involvement when compared with 
euthyroid women. Moreover, hypothyroid patients who devel-
oped breast cancer progressed with a more indolent disease 
and smaller tumors. On the other hand, Shering et al (18) and 
Ito and Maruchi (17) observed that Japanese women with 
Hashimoto's thyroiditis had a higher incidence of mammary 
cancer than women without thyroid disease. Two recent 
meta-analyses showed no significant association, except for 
autoimmune thyroiditis which increased breast cancer risk; 
however, the heterogeneity of the studies analyzed precludes 
firm conclusions (7,22).
Our study failed to show a statistically significant asso-
ciation between hyperthyroidism and breast carcinogenesis. In 
contrast, two studies found a correlation between the adminis-
tration of THs and increased risk of mammary cancer (23,24). 
The results of epidemiological studies concerning hyper-
thyroidism in relation to breast cancer are unclear and 
seem to depend on the inclusion of pre- or post-menopausal 
patients (25). The authors speculated that subclinical hyperthy-
roidism in postmenopausal women contributed to mammary 
tumor growth as a result of an E2-like effect through the inter-
actions between T3/T4 and ER. In vitro interactions between 
T3 and ER have been reported in breast cancer cell lines (19). 
Notably, in our present study, circulating E2 was significantly 
reduced in HyperT rats even when mammary carcinogenesis 
similar to EUT rats was observed. This result supports the role 
of TH as an E2-like factor in mammary tumor growth.
The mechanism whereby the thyroid gland influences 
mammary tumorigenesis is unclear. However, our results 
suggest that different thyroid states affect breast tumorigenesis 
by altering body growth, breast morphology, body composition 
and adipocytoquine release, and patterns of secretion of other 
hormones such as E, Pg, PRL and/or GH, among others.
Body growth. GH is required for mammary development since 
it stimulates ductal growth, proliferation and secretion (26). 
The effect of GH on mammary development is in part medi-
ated by insulin-like growth factor 1 (IGF-1), and the action of 
E2 and Pg are dependent upon IGF-1 (27). GH stimulates IGF-1 
secretion in the liver and in the mammary stroma, therefore a 
paracrine role of GH modulating the effects of other hormones 
on proliferation and differentiation of mammary epithelium 
must not be ruled out (28). The present results demonstrated 
that hypothyroidism diminishes the secretion of GH in the rat, 
supporting previous studies (29).
Clinical evidence suggests that high circulating levels of 
GH/IGF-1 are associated with an increased risk of subse-
quently developing breast cancer (30). In studies in vitro, 
human GH was found to promote mammary carcinoma 
cell proliferation in an autocrine/paracrine manner (31) and 
resulted in a phenotypic conversion of human mammary carci-
noma cells into a more invasive phenotype (32). In our in vivo 
study, we observed retardation in body growth associated with 
a significant decrease in serum GH levels in HypoT rats, which 
also had a lower incidence of mammary cancer.
Breast morphology. Breast development occurs through a 
process of ductal elongation, branching and sprouting of 
ductules or alveoli, a process that requires extensive cell 
proliferation and penetration of the ductal epithelium into the 
stroma (33). Ductal elongation is directed by E2, GH, IGF-1 
and epidermal growth factor (EGF), whereas ductal branching 
and alveolar budding are influenced by additional factors such 
as Pg, PRL and THs. The stroma of the mammary gland is 
a complex structure composed of an extracellular matrix and 
a variety of cell types including endothelial cells, inflamma-
tory cells, fibroblasts, fibroblast-like cells and adipocytes (34). 
This compartment can also be referred to as the mammary fat 
pad (34) since it mainly contains adipose tissue (35).
The response by the ductal epithelium to various hormones 
and growth factors is modulated by epithelial-stromal interac-
tions, which seem to be bidirectional (36). It is expected that 
the marked variations in the epithelial-stroma ratio influence 
the bidirectional connection leading to specific modifications 
in gene expression that may account for the different suscepti-
bility or risk to develop breast cancer (33).
In the present study, we observed that hypothyroidism 
retarded the growth of the ductal system and induced an 
increase in mammary gland fat deposit. In accordance, 
Vonderhaar and Greco (37,38) noticed that the gland of 
primiparous hypothyroid adult mice retained a primitive 
ductal appearance, i.e. that the epithelial component consisted 
of a sparse ductal system with few branches filling about 
one-fourth of the fat pad. Coincident with our results, they also 
described that while glands from hyperthyroid and euthyroid 
virgin animals preserved a small degree of ductal branching 
with primitive alveoli, the glands from hypothyroid animals 
showed less ductal branching and were devoid of alveoli (37). 
Thus, the decrease in mammary tumor incidence in our HypoT 
rats may be due to the reduced development of the mammary 
gland and the decrease in the parenchyma-stroma ratio.
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Body composition and adipocytokine secretion. THs have 
important effects on energy balance, since they influence both 
energy intake and expenditure. Severe hypothyroidism in the 
rat causes a sharp drop in food intake and metabolism, and 
this consequently suppresses the growth of DMBA-induced 
mammary cancer (11). Accordingly, in the present study, 
we observed a decreased food intake and body weight in 
HypoT rats in comparison with the controls and the HyperT 
animals. Calorie restriction was found to decrease prolifera-
tion and angiogenesis and increases apoptosis in mammary 
tumors (39).
Many changes related to energy homeostasis, body weight 
and food intake are associated with alterations in the function 
of adipose tissue. Leptin is the obese gene product secreted 
exclusively by adipocytes. Accumulating evidence shows 
that leptin is an important pro-angiogenic, pro-inflammatory 
and mitogenic factor, whose actions are reinforced through 
crosstalk with cytokines/growth factors (40). Increasing leptin 
levels activate the thyroid, GH, and gonadal axes (41). Thus, 
it is conceivable that leptin may have a role in different states 
of thyroidal disease. This relationship has been the subject of 
several studies, but no uniform picture has yet emerged from 
the results. Valcavi et al (42) reported significantly reduced 
serum leptin concentrations before and during replacement 
therapy in patients with hypothyroidism. Other authors did not 
observe alterations in serum leptin in different hypothyroid 
conditions (43) and Leonhardt et al (44) described increased 
leptin concentrations in patients with primary hypothyroidism 
or thyroid carcinoma compared with euthyroid controls.
In hypothyroid Wistar rats, a decrease in metabolizable 
energy intake and energy expenditure together with a shift in 
lipid and protein partitioning was found after 7 and 15 days of 
treatment with PTU (11). Consequently, body lipid percentage 
significantly increased compared to euthyroid rats. Our 
results in Sprague-Dawley rats showed that, even though the 
animals treated with PTU had a lower body weight than the 
controls, the percentage of body fat was similar in the three 
studied groups. However, adipose tissue of the HypoT rats 
appeared to be dysfunctional, attending to the lower amount 
of leptin expressed per gram of fat and the diminished serum 
levels of leptin in these animals. This fact can be one of 
the possible mechanisms related to the increased latency in 
HypoT rats since leptin has been shown to inhibit apoptosis 
and to stimulate growth (45) and also angiogenesis in breast 
carcinogenesis (46). However, in our in vivo study, we did not 
observe changes in tumor cell proliferation as evaluated by the 
mitotic index and by a more sensitive method, PCNA immu-
nostaining. In turn, in cancer cells of our HypoT rats apoptosis 
was augmented in an inverse relation to serum leptin levels. In 
support of our results, it has been described that leptin inhibits 
apoptosis and this action is correlated with increased expres-
sion of anti-apoptotic protein Bcl-2 (47).
To summarize, dysfunctional body fat secreting lower 
levels of leptin may be another factor responsible for the 
delayed development of mammary tumors in HypoT rats. We 
cannot rule out the possible role of the stroma in the production 
of adipokines as tumor growth factors. Ongoing studies in our 
laboratory aim to evaluate the involvement of leptin locally 
produced by the peritumoral fat pad in the autocrine/paracrine 
regulation of tumor growth.
Hormones targeting the mammary gland. In the present 
study, we demonstrated that chronic hypothyroidism induced 
by PTU treatment modifies certain hormone patterns. E2, 
which plays an essential role in mammary gland development 
and carcinogenesis, was diminished in HypoT rats. E2 and 
Pg are known to promote proliferation and differentiation in 
the normal breast. Most breast cancers are initially hormone 
dependent and it is well accepted that E2 plays a crucial role in 
their development and progression (48). E2 exerts carcinogenic 
effects by simultaneously increasing the number of DNA 
replication errors by stimulating cell proliferation and gene 
expression; and through its oxidative metabolism that forms 
DNA damaging species (49).
There is evidence that Pg and its related signaling pathways 
are important players in the induction, progression and mainte-
nance of the neoplastic phenotype in the mammary gland (50). 
However, in our in vivo study we did not find any relationship 
between circulating Pg and mammary carcinogenesis in rats 
with different thyroid disorders.
On the other hand, PRL secretion during diestrus was not 
affected in our experimental thyroid conditions. It has been 
previously shown that hypothyroidism can increase serum 
levels of PRL during estrous without changing basal secre-
tion on diestrous day (29). In the present study, based on the 
similar values of circulating PRL between the treatments, we 
cannot attribute a relevant role of this hormone on mammary 
carcinogenesis. Moreover, we did not observe any significant 
differences in serum PRL in rats with and without tumors; 
further supporting the minor role of PRL in breast cancer 
development in HypoT rats.
In conclusion, our results to date show that hypothyroidism 
alters animal growth, breast morphology, body composition 
and adipocytoquine secretion and serum E2 enhancing apop-
tosis, consequently retarding mammary carcinogenesis in rats. 
Additional studies by us are currently underway to investigate 
the involved molecular mechanisms.
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